Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Total revenues	$ 0	$ 0	$ 0	$ 0
Total cost of revenue	0	0	0	0
Gross loss	0	0	0	0
Research and development expense	1,415,000	1,679,000	3,060,000	3,143,000
Selling, general and administrative expense	1,556,000	1,670,000	3,195,000	3,151,000
Operating loss	(3,077,000)	(5,027,000)	(6,058,000)	(9,481,000)
Other income (expense):
Warrant revaluation income (expense)	91,000	(9,677,000)	326,000	(9,723,000)
Derivative revaluation income	242,000	853,000	179,000	541,000
Interest expense	(191,000)	(185,000)	(381,000)	(368,000)
Other income, net	41,000	18,000	139,000	6,000
Loss before income taxes	(2,894,000)	(14,018,000)	(5,795,000)	(19,025,000)
Income taxes	0	0	0	0
Net loss	(2,894,000)	(14,018,000)	(5,795,000)	(19,025,000)
Dividend paid in-kind to preferred stockholders	(83,000)	(80,000)	(165,000)	(100,000)
Deemed dividend on preferred stock (see Note 10)	(126,000)	(136,000)	(247,000)	(3,870,000)
Net loss attributable to common stockholders	$ (3,103,000)	$ (14,234,000)	$ (6,207,000)	$ (22,995,000)
Net loss:
Basic (usd per share)	$ (0.49)	$ (4.84)	$ (1.03)	$ (7.82)
Diluted (usd per share)	$ (0.49)	$ (4.84)	$ (1.03)	$ (7.82)
Weighted average number of common shares outstanding:
Basic (shares)	6,376,048	2,940,899	6,026,454	2,940,763
Diluted (shares)	6,376,048	2,940,899	6,026,454	2,940,763
Affiliated Entity
Research and development expense	$ 106,000	$ 1,678,000	$ (197,000)	$ 3,187,000